⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 9, 2025EBioMedicineOpen Access

Preclinical evaluation of long-acting cabotegravir and rilpivirine for HIV post-exposure prophylaxis in a macaque model

Priya Srinivasan Jining Zhang Tiancheng Edwards Chuong Dinh A. J. E. Green Dawn Little Tyana Singletary Maria Mendoza Yi Pan Frank Deyounks Ryan Johnson Jonathan Lipscomb Athena P. Kourtis Walid Heneine J. Gerardo García‐Lerma James M. Smith

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the efficacy of long-acting cabotegravir and rilpivirine for HIV post-exposure prophylaxis.
Preclinical evaluation using a macaque model
Administration of cabotegravir and rilpivirine
Assessment of HIV prevention outcomes
Demonstrated effectiveness of rilpivirine for HIV post-exposure prophylaxis
Support for long-acting formulations in preventing HIV transmission

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Preclinical evaluation of rilpivirine for HIV post-exposure prophylaxis in macaque models, suggesting potential effectiveness.

Abstract

This work was funded by CDC intramural funds.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Srinivasan et al. (2025) studied this question.

synapsesocial.com/papers/69401efa2d562116f28f9990 https://doi.org/10.1016/j.ebiom.2025.106067

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study2024 · 11 citations
2Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trialRCT · 2025 · 15 citations
3Modulation and distribution of extracellular free water and tract deficits in rhesus macaques before and after the initiation of emtricitabine + tenofovir disoproxil fumarate + dotutegravir treatmentOriginal Research · 2025
4Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure ProphylaxisOriginal Research · 2024 · 41 citations
5Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People with HIV Who Are Virally Unsuppressed2024 · 31 citations

More related papers

Longitudinal profiling of blood-tissue HIV-1 reservoirs reveals the mechanism of failure to long-acting cabotegravir/rilpivirine: a case report2026
Indirect Treatment Comparison of the Efficacy of Long-Acting Injectable Cabotegravir Compared With Lenacapavir for HIV Pre-exposure Prophylaxis2026
Pediatric <scp>NHP</scp> Workshop—“ <scp>NHP</scp> Models for <scp>HIV</scp> Prevention and Treatment: Towards Developing Pediatric Formulations”, New Orleans, <scp>LA</scp> , October 22, 2024: Summary of Proceeding—Session <scp>IV</scp> : Challenges of the Juvenile <scp>NHP</scp> Models2026

More from EBioMedicine

Genetically informed therapy for valvular heart disease: what, where, and when to targetTue,
Relationship extraction for adverse drug events in clinical notes using large language models: a retrospective cross-sectional studySat,